Oral Mucosal Melanoma: clinico-pathological analysis of 30 cases in a single center
Roger Kruger de Lima, Ana Lucia Noronha Francisco, Marcus Vinicius Furlan, Silvia Vanessa Lourenço, Clóvis Antônio Lopes Pinto, Luiz Paulo Kowalski, Mauro Kasuo Ikeda
Abstract
Introduction: Oral mucosa melanoma (OMM) is a rare and aggressive disease comprising 0.26% of all head and neck malignant neoplasms. Affected individuals usually present younger than the other individuals with mucosal melanoma. Surgical treatment with extensive surgical resection was defended as the primary treatment modality, with increasing consideration for postoperative radiotherapy. Objective: The objective of this retrospective study with 30 subjects treated at the A.C. Camargo Cancer Center from 1954 to 2014 was to analyze the characteristics and treatments related to the tumor that could be identified as risk factors for the prognosis and consequently the overall survival. Materials and Methods: The data collected were analyzed by the STATA v.12.0 program and the Kaplan-Meier curves and the log rank test were used to compare the survival curves. Of the 30 cases of oral melanoma, 56.7% (17) were men and 43.3% (13) women with a mean age of 59.7% (19 to 88 years). Regarding the symptomatology in the moment of diagnosis, 53.3% (16) of the individuals denied pain and 60% (18) bleeding. Results: Considering the morphological aspects of the lesions, it was observed that 43.3% (13) had a non-ulcerated surface, 93.3% (28) were pigmented and 63.3% (19) were nodular type. From all cases, 33.3% (10) were classified as T3 tumors and 66.7% (20), as T4. Fifty-six point seven percent (17) of the lesions had slow growth and 46.6% (14) of the individuals had palpable lymph node at the time of diagnosis. Twenty three patients (76.7%) underwent radical surgery; 16.7% (5) only cryotherapy and 6.6% (2) chemotherapy. Conclusion: In this study we observed 23 recurrences and identified as significant factors for survival: ulceration, the T stage, the presence of N+ and the modality of therapy.
Keywords
References
1. Gavriel H, McArthur G, Sizeland A, Henderson M. Review: mucosal melanoma of the head and neck. Melanoma Res. 2011;21(4):257-66. http://dx.doi.org/10.1097/CMR.0b013e3283470ffd. PMid:21540752.
2. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer. 1997;80(8):1373-86. http://dx.doi.org/10.1002/(SICI)1097-0142(19971015)80:8<1373::AID-CNCR3>3.0.CO;2-G. PMid:9338460.
3. Andersen LJ, Berthelsen A, Hansen HS. Malignant melanoma of the upper respiratory tract and the oral cavity. J Otolaryngol. 1992;21(3):180-5. PMid:1404568.
4. Sortino-Rachou AM, Cancela MC, Voti L, Curado MP. Primary oral melanoma: population-based incidence. Oral Oncol. 2009;45(3):254-8. http://dx.doi.org/10.1016/j.oraloncology.2008.04.015. PMid:18675580.
5. Sun CZ, Chen YF, Jiang Y, Hu ZD, Yang AK, Song M. Treatment and prognosis of oral mucosal melanoma. Oral Oncol. 2012;48(7):647-52. http://dx.doi.org/10.1016/j.oraloncology.2012.01.019. PMid:22349277.
6. Francisco AL, Furlan MV, Peresi PM, Nishimoto IN, Lourenço SV, Pinto CA, Kowalski LP, Ikeda MK. Head and neck mucosal melanoma: clinico-pathological analysis of 51 cases treated in a single cancer center and review of the literature. Int J Oral Maxillofac Surg. 2016;45(2):135-40. http://dx.doi.org/10.1016/j.ijom.2015.08.987. PMid:26655030.
7. Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck. 2008;30(12):1592-8. http://dx.doi.org/10.1002/hed.20910. PMid:18798304.
8. Papaspyrou G, Garbe C, Schadendorf D, Werner JA, Hauschild A, Egberts F. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors. Melanoma Res. 2011;21(6):475-82. http://dx.doi.org/10.1097/CMR.0b013e32834b58cf. PMid:21897303.
9. Postow MA, Hamid O, Carvajal RD. Mucosal melanoma: pathogenesis, clinical behavior, and management. Curr Oncol Rep. 2012;14(5):441-8. http://dx.doi.org/10.1007/s11912-012-0244-x. PMid:22661391.
10. Lund VJ, Howard DJ, Harding L, Wei WI. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope. 1999;109(2 Pt 1):208-11. PMid:10890767.
11. International Union Against Cancer. TNM classification of malignant tumours. 7th ed. Geneva: UICC.
12. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer. 1998;83(8):1664-78. http://dx.doi.org/10.1002/(SICI)1097-0142(19981015)83:8<1664::AIDCNCR23>3.0.CO;2-G. PMid:9781962.
13. Breik O, Sim F, Wong T, Nastri A, Iseli TA, Wiesenfeld D. Survival outcomes of mucosal melanoma in the head and neck: case series and review of current treatment guidelines. J Oral Maxillofac Surg. 2016;74(9):1859-71. http://dx.doi.org/10.1016/j.joms.2016.03.008. PMid:27063590.
14. Kerr EH, Hameed O, Lewis JS Jr, Bartolucci AA, Wang D, Said-Al-Naief N. Head and neck mucosal malignant melanoma: clinicopathologic correlation with contemporary reviw of prognostic indicators. Int J Surg Pathol. 2012;20(1):37-46. http://dx.doi.org/10.1177/1066896911417970. PMid:21862490.
15. López F, Rodrigo JP, Cardesa A, Triantafyllou A, Devaney KO, Mendenhall WM, Haigentz M Jr, Strojan P, Pellitteri PK, Bradford CR, Shaha AR, Hunt JL, de Bree R, Takes RP, Rinaldo A, Ferlito A. Update on primary head and neck mucosal melanoma. Head Neck. 2016;38(1):147-55. http://dx.doi.org/10.1002/hed.23872. PMid:25242350.
16. Konuthula N, Khan MN, Parasher A, Del Signore A, Genden EM, Govindaraj S, Iloreta AM. The presentation and outcomes of mucosal melanoma in 695 patients. Int Forum Allergy Rhinol. 2017;7(1):99-105. http://dx.doi.org/10.1002/alr.21831. PMid:27628440.
17. Jethanamest D, Vila PM, Sikora AG, Morris LG. Predictors of survival inmucosal melanoma of the head and neck. Ann Surg Oncol. 2011;18(10):2748-56. http://dx.doi.org/10.1245/s10434-011-1685-4. PMid:21476106.
18. Patel SG, Prasad ML, Escrig M, Singh B, Shaha AR, Kraus DH, Boyle JO, Huvos AG, Busam K, Shah JP. Primary mucosal malignant melanoma of the head and neck. Head Neck. 2002;24(3):247-57. http://dx.doi.org/10.1002/hed.10019. PMid:11891956.
19. Shuman AG, Light E, Olsen SH, Pynnonen MA, Taylor JM, Johnson TM, Bradford CR. Mucosal melanoma of the head and neck: predictors of prognosis. Arch Otolaryngol Head Neck Surg. 2011;137(4):331-7. http://dx.doi.org/10.1001/archoto.2011.46. PMid:21502471.
20. Shiga K, Ogawa T, Kobayashi T, Ueda S, Kondo A, Nanba A, Kuwashima S, Asada Y, Suzuki S, Nagahashi T, Takahashi M, Suzuki M, Ishida A, Watanabe K, Harabuchi Y, Himi T, Sinkawa H, Sato H, Saijo S, Fukuda S, Tanaka K, Ishikawa K, Omori K, Aoyagi M, Hashimoto S. Malignant melanoma of the head and neck: A Multi-institutional retrospective analysis of cases in Northern Japan. Head Neck. 2012;34(11):1537-41. http://dx.doi.org/10.1002/hed.21984. PMid:22473987.
21. Penel N, Mallet Y, Mirabel X, Van JT, Lefebvre JL. Primary mucosal melanoma of head and neck: prognostic value of clear margins. Laryngoscope. 2006;116(6):993-5. http://dx.doi.org/10.1097/01.mlg.0000217236.06585.a9. PMid:16735914.
22. Moreno MA, Hanna EY. Management of mucosal melanomas of the head and neck: did we make any progress? Curr Opin Otolaryngol Head Neck Surg. 2010;18(2):101-6. http://dx.doi.org/10.1097/MOO.0b013e3283374d31. PMid:20234212.
23. Tajudeen BA, Vorasubin N, Sanaiha Y, Palma-Diaz MF, Suh JD, Wang MB. Sinonasal mucosal melanoma: 20-year experience at a tertiary referral center. Int Forum Allergy Rhinol. 2014;4(7):592-7. http://dx.doi.org/10.1002/alr.21324.PMid:24664639.
24. Gilain L, Houette A, Montalban A, Mom T, Saroul N. Mucosal melanoma of the nasal cavity and paranasal sinuses. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131(6):365-9. http://dx.doi.org/10.1016/j.anorl.2013.11.004. PMid:24906226.
25. Douglas CM, Malik T, Swindell R, Lorrigan P, Slevin NJ, Homer JJ. Mucosal melanoma of the head andneck: radiotherapy or surgery? J Otolaryngol Head Neck Surg. 2010;39(4):385-92. PMid:20643003.
26. Combs SE, Konkel S, Thilmann C, Debus J, Schulz-Ertner D. Local high-dose radiotherapy and sparing of normal tissue using intensity-modulated radiotherapy (IMRT) for mucosal melanoma of the nasal cavity and paranasal sinuses. Strahlenther Onkol. 2007;183(2):63-8. http://dx.doi.org/10.1007/s00066-007-1616-2. PMid:17294109.
27. Yanagi T, Mizoe JE, Hasegawa A, Takagi R, Bessho H, Onda T, Kamada T, Okamoto Y, Tsujii H. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys. 2009;74(1):15-20. http://dx.doi.org/10.1016/j.ijrobp.2008.07.056. PMid:19046826.
28. Liao JJ, Parvathaneni U, Laramore GE, Thompson JA, Bhatia S, Futran ND, Bhrany AD, Hawes SE, Ladra M. Fast neutron radiotherapy for primary mucosal melanomas of the head and neck. Head Neck. 2014;36(8):1162-7. http://dx.doi.org/10.1002/hed.23428. PMid:23852725.
29. Zenda S, Kawashima M, Nishio T, Kohno R, Nihei K, Onozawa M, Arahira S, Ogino T. Proton Beam Therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study. Int J Radiat Oncol Biol Phys. 2011;81(1):135-9. http://dx.doi.org/10.1016/j.ijrobp.2010.04.071. PMid:20950948.
30. Krengli M, Jereczek-Fossa BA, Kaanders JH, Masini L, Beldì D, Orecchia R. What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit Rev Oncol Hematol. 2008;65(2):121-8. http://dx.doi.org/10.1016/j.critrevonc.2007.07.001. PMid:17822915.
31. Suit HD. Local control and patient survival. Int J Radiat Oncol Biol Phys. 1992;23(3):653-60. http://dx.doi.org/10.1016/0360-3016(92)90025-D. PMid:1612967.
32. Wu AJ, Gomez J, Zhung JE, Chan K, Gomez DR, Wolden SL, Zelefsky MJ, Wolchok JD, Carvajal RD, Chapman PB, Wong RJ, Shaha AR, Kraus DH, Shah JP, Lee NY. Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol. 2010;33(3):281-285. PMid:19823070.
33. Li W, Yu Y, Wang H, Yan A, Jiang X. Evaluation of the prognostic impact of post-operativeadjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis. BMC Cancer. 2015;15(1):758. http://dx.doi.org/10.1186/s12885-015-1750-7. PMid:26490539.
34. Green B, Elhamshary A, Gomez R, Rahimi S, Brennan PA. Anupdate on the current management of head and neck mucosal melanoma. J Oral Pathol Med. 2017;46(7):475-9. http://dx.doi.org/10.1111/jop.12526. PMid:27864904.
35. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S. Phase II openlabel, single arm trial of imatinibmesylate in patients with metastatic melanoma harbouring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-9. http://dx.doi.org/10.1200/JCO.2010.33.9275. PMid:21690468.
36. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, Van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. http://dx.doi.org/10.1056/NEJMoa1003466. PMid:20525992.
37. Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer. 2014;50(1):121-7. http://dx.doi.org/10.1016/j.ejca.2013.09.007. PMid:24100024.
38. Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2014;2(1):15-8. http://dx.doi.org/10.1158/2326-6066. CIR-13-0146. PMid:24778161.
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email